Six-week open-label reboxetine treatment in children and adolescents with attention-deficit/hyperactivity disorder.

Six-week open-label reboxetine treatment in children and adolescents with attention-deficit/hyperactivity disorder.

Item
http://www.wikidata.org/entity/Q34412884
The adult psychiatrist's dilemma: psychostimulant use in attention deficit/hyperactivity disorderA systematic review of reboxetine for treating patients with attention deficit hyperactivity disorderDo adrenergically active drugs have a role in the first-line treatment of attention-deficit/hyperactivity disorder?A systematic review of randomized controlled trials of bupropion versus methylphenidate in the treatment of attention-deficit/hyperactivity disorderEfficacy of reboxetine in adults with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled clinical trial.Drug therapy of attention deficit hyperactivity disorder: current trends.Innovations and recent trends in the treatment of ADHD.Triple reuptake inhibitors as potential next-generation antidepressants: a new hope?An 11-year retrospective review of venlafaxine ingestion in children from the California Poison Control System.Effectiveness of reboxetine in treatment of outpatient children and adolescents with attention deficit-hyperactivity disorder with comorbid anxiety disorders.Reboxetine in therapy-resistant enuresis: a retrospective evaluation.The effects of reboxetine treatment on depression-like behavior, brain neurotrophins, and ERK expression in rats exposed to chronic mild stress.
P2860

Six-week open-label reboxetine treatment in children and adolescents with attention-deficit/hyperactivity disorder.

Item
http://www.wikidata.org/entity/Q34412884
description
2005 nî lūn-bûn
@nan
2005 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Six-week open-label reboxetine ...... eficit/hyperactivity disorder.
@ast
Six-week open-label reboxetine ...... eficit/hyperactivity disorder.
@en
Six-week open-label reboxetine ...... eficit/hyperactivity disorder.
@nl
type
label
Six-week open-label reboxetine ...... eficit/hyperactivity disorder.
@ast
Six-week open-label reboxetine ...... eficit/hyperactivity disorder.
@en
Six-week open-label reboxetine ...... eficit/hyperactivity disorder.
@nl
prefLabel
Six-week open-label reboxetine ...... eficit/hyperactivity disorder.
@ast
Six-week open-label reboxetine ...... eficit/hyperactivity disorder.
@en
Six-week open-label reboxetine ...... eficit/hyperactivity disorder.
@nl
P1433
P1476
P2093
P304
P31
P356
P433
P478
P577
P5875
P698
P921
P356
P1433
P1476
Six-week open-label reboxetine ...... eficit/hyperactivity disorder.
@en
P2093
P304
P31
P356
10.1097/01.CHI.0000155327.30017.8C
P433
P478
P577
P5875
P698
P921